A Guide to Successful Collaboration - Considerations When Choosing Your First CDMO as a Start-Up

In Philadelphia in May on site at CPHI North America we were able to meet with some of our speakers regarding their presentations. In the following interview Srinivasan Shanmugam, Executive Director, Pharmaceutical Sciences, Business Support, and New Technologies at Adare Pharma Solutions discusses his breakfast session. 

Explore Adare's capabilities through our interactive brochure, showcasing our technology-driven CDMO with integrated end-to-end services. With extensive capacity, experience, and a global track record, Adare is your partner for small molecule oral solid dose success.

Throughout CPHI North America 2023, several Breakfast Sessions were held to start the day off right with a complimentary breakfast and a networking and learning session for our attendees. With insightful presentations from industry experts and partners, the CPHI North America Breakfast Sessions had something for everyone looking to fill their brains and their stomachs. 

Follow along for live updates from the Content team as we bring you the latest from CPHI North America 2023 - from session talks, panel discussions, interviews, and more, there's a lot to discover with CPHI Online at the Pennsylvania Convention Center! 

The following session has been SOLD OUT. For any inquiries, please contact a member of staff on the day Kickstart your CPHI North America with a coffee and pastry, connect with your peers, and listen to exclusive content surrounding patient-centric development The challenge of ensuring medication acceptance and adherence is particularly acute in special populations, such as pediatric and geriatric groups. These populations exhibit distinct pharmacokinetic and pharmacodynamic profiles due to their unique age-related physiological and biopharmaceutical characteristics. Consequently, the standard approaches to medication formulation often fall short of addressing their specific needs. This presentation will explore the unique aspects of pediatric and geriatric populations, highlighting the limitations encountered in the design and development of dosage forms tailored for them, and how those challenges are overcome. A significant focus will be placed on the strategies that can be employed to overcome these challenges, with an emphasis on Adare’s platform technologies. Through this discussion, we aim to shed light on the critical factors that must be considered in the development of effective, patient-friendly pharmaceutical formulations for pediatric and geriatric patients.